IP Library › Patent Application 11554521
Patent Application
App. No. 11/554,521

Interferon-Alpha Polypeptides and Conjugates

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/554,521
Abstract

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Claims (35)

1 .- 34 . (canceled)

35 . A method for reducing the level of a virus in the serum of a patient infected with the virus, comprising administering to the patient a polypeptide in an amount effective to reduce the level of virus in the serum compared to the level present prior to the start of treatment, wherein the polypeptide comprises a sequence which differs in 0 to 16 amino acid positions from the sequence of SEQ ID NO:10 and wherein the polypeptide exhibits an interferon-alpha activity, wherein the interferon-alpha activity is an anti-viral activity.

36 . The method of claim 35 wherein the virus is Hepatitis C Virus.

37 . The method of claim 35 wherein the virus is Hepatitis B Virus.

38 . The method of claim 35 wherein the virus is Human Immunodeficiency Virus.

39 . A method for reducing the level of a virus in the serum of a patient infected with the virus, comprising administering to the patient a conjugate in an amount effective to reduce the level of virus in the serum compared to the level present prior to the start of treatment, wherein the conjugate comprises:

a) a polypeptide comprising a sequence which differs in 0 to 16 amino acid positions from the sequence of SEQ ID NO:10; and

b) a non-polypeptide moiety covalently attached to the polypeptide, and wherein the conjugate exhibits an interferon-alpha activity, wherein the interferon-alpha activity is an antiviral activity.

40 . The method of claim 39 wherein the virus is Hepatitis C Virus.

41 . The method of claim 39 wherein the virus is Hepatitis B Virus.

42 . The method of claim 39 wherein the virus is Human Immunodeficiency Virus.

43 . The method of claim 40 wherein the non-polypeptide moiety is a polymer.

44 . The method of claim 43 wherein the polymer is polyethylene glycol.

45 . The method of claim 44 wherein a polyethylene glycol moiety is covalently attached to a cysteine residue.

46 . The method of claim 44 wherein a polyethylene glycol moiety is covalently attached to a lysine residue or to the N-terminal amino group.

47 . The method of claim 44 wherein a polyethylene glycol moiety is covalently attached to a lysine residue.

48 . The method of claim 44 wherein a polyethylene glycol moiety is covalently attached to the N-terminal amino group.

49 . The method of claim 44 , wherein at least two polyethylene glycol moieties are attached to the polypeptide and wherein each polyethylene glycol moiety is covalently attached to a different amino acid residue of the polypeptide.

50 . The method of claim 49 , wherein the at least two polyethylene glycol moieties are attached to different lysine residues.

51 . The method of claim 49 , wherein one of the at least two polyethylene glycol moieties is attached to the N-terminal amino group and one of the at least two polyethylene glycol moieties is attached to a lysine residue.

52 . A method of treating a patient infected with Hepatitis C Virus comprising administering to the patient a pharmaceutically acceptable excipient and a therapeutically effective amount of a conjugate, wherein the conjugate comprises:

a) a polypeptide comprising a sequence which differs in 0 to 16 amino acid positions from the sequence of SEQ ID NO:10; and

b) a non-polypeptide moiety covalently attached to the polypeptide,

and wherein the conjugate exhibits an interferon-alpha activity, wherein the interferon-alpha activity is an antiviral activity.

53 . The method of claim 52 wherein the conjugate is administered by weekly subcutaneous injection.

54 . The method of claim 52 wherein the conjugate is administered by subcutaneous injection every two weeks.

55 . The method of claim 52 wherein the non-polypeptide moiety is a polymer.

56 . The method of claim 55 wherein the polymer is polyethylene glycol.

57 . The method of claim 56 wherein a polyethylene glycol moiety is covalently attached to a cysteine residue.

58 . The method of claim 56 wherein a polyethylene glycol moiety is covalently attached to a lysine residue or to the N-terminal amino group.

59 . The method of claim 56 wherein a polyethylene glycol moiety is covalently attached to a lysine residue.

60 . The method of claim 56 wherein a polyethylene glycol moiety is covalently attached to the N-terminal amino group.

61 . The method of claim 56 , wherein at least two polyethylene glycol moieties are attached to the polypeptide and wherein each polyethylene glycol moiety is covalently attached to a different amino acid residue of the polypeptide.

62 . The method of claim 61 , wherein the at least two polyethylene glycol moieties are attached to different lysine residues.

63 . The method of claim 61 , wherein one of the at least two polyethylene glycol moieties is attached to the N-terminal amino group and one of the at least two polyethylene glycol moieties is attached to a lysine residue.